Sitosterolemia and xanthomatosis together are a disease characterized by premature cardiovascular disease, and by elevated plasma concentrations of total sterols and of plant sterols, especially sitosterol which is hyperabsorbed. In order to determine whether this abnormal metabolism also involved other sterols, a patient with sitosterolemia was fed a diet high in shellfish that contain significant quantities of noncholesterol sterols, some of which are less well absorbed than cholesterol in humans. Compared with control subjects (n = 8), the sitosterolemic subject had an increased absorption of 22-dehydrocholesterol (71.5% vs. 43.8±11A%, mean±SD), C-26 sterol (80.6% vs. 493±11.4%), brassicasterol (51.8% vs. 4.8±4.2%), and 24-methylene cholesterol (60.5% vs. 16.0±8.3%). This enhanced absorption was associated with an increased plasma total shellfish sterol level (13.1 mg/dl vs. 1.9±0.7 mg/dl in normals). In the sitosterolemic subject, as in normals, the shellfish sterols were not preferentially concentrated in any lipoprotein class, and 50-65% of these sterols were in the esterified form in plasma. Bile acids and neutral sterols were quantitated in bile obtained by duodenal aspiration. The bile acid composition did not differ significantly in the sitosterolemic subject compared with the normal controls. The sitosterolemic subject, though, was unable to concentrate normally the neutral shellfish sterols in bile. The normal controls concentrated the shellfish sterols in bile 63±1.7-fold relative to the plasma shellfish sterol concentration whereas the study subject was only able to concentrate them 2.1-fold. We propose that sitosterolemia and xanthomatosis occur from a generalized abnormality in the usual ability of the gut mucosa and other tissues of the body to discriminate among many different sterols. This has important implications for the understanding of the pathophysiology of this disease and for therapeutic recommendations.
Introduction
Sitosterolemia and xanthomatosis together are a rare familial disease characterized by the development of xanthomas at an early age, premature cardiovascular disease, elevated plasma sterol concentrations with markedly elevated concentrations of plant sterols, and an increased absorption and decreased excretion of sitosterol (1) (2) (3) (4) (5) . Campesterol, stigmasterol, avenasterol, cholestanol, sitostanol, and campestanol have been found, in addition to sitosterol, in the plasma ofsome or all ofthese patients (1) (2) (3) (4) (5) (6) . The family studies are most consistent with this disease being inherited as an autosomal recessive disorder (1) (2) (3) (4) (5) , and the heterozygous subjects have been reported to have hyperapobetalipoproteinemia (4) . Sitosterol differs from cholesterol by the presence of an ethyl group at carbon 24 of cholesterol. This change in the sterol structure results in a marked reduction in dietary sitosterol absorption, compared with dietary cholesterol, a preferential excretion of sitosterol in bile, and a sitosterol level of <1% of total plasma sterols in normal humans (7) . Sitosterolemia subjects have been shown to absorb 19-30% of dietary sitosterol (1) (2) (3) 5) , and sitosterol has comprised 8-26% of total plasma sterols (1) (2) (3) (4) (5) (6) . In addition, subjects with sitosterolemia have been shown to have a defect in the biliary excretion of sitosterol (3, 5) .
Some ofthe potential sites for regulation ofsterol absorption, transport, storage, and excretion include (a) intraluminal solubilization of sterols by bile acids in the small intestine, (b) a sterol recognition site on cell membranes, (c) intracellular sterol carrier or binding proteins, (d) acyl CoA:cholesterol acyltransferase (ACAT)' (EC 2.3.1.26), (e) neutral cholesteryl ester hydrolase (NCEH) (EC 3.1.1.13), and (f) enzymes involved in bile acid synthesis. It is unknown whether one of these is the site of the molecular defect in sitosterolemia subjects. In addition to the site of the molecular defect in this disease, other unknown aspects include: (a) Does the defect express itself in many different tissues in the body or involve only the gastrointestinal tract? (b) Is the abnormality specific for sitosterol or is it more generalized to affect other plant and animal sterols?
Certain shellfish (clams, oysters, scallops) contain a number of sterols not normally found in human tissues (Fig. 1 ). These sterols include 22-dehydrocholesterol, brassicasterol, 22-trans-24-norcholesta-5,22-dien-3 ,B-ol (C-26 sterol), and 24-methylene cholesterol, and they comprise >50% of the total tissue sterols ofthese organisms (8) . In order to ascertain the ability ofsubjects with sitosterolemia to absorb and excrete these sterols, and to gain further insights into the pathogenesis of this disease, the following studies were performed.
Methods
Experimental subjects. A 38-year-old woman with sitosterolemia and xanthomatosis who has been previously reported, participated in these experiments (2) . The patient was initially diagnosed as having hyperbetalipoproteinemia, but in 1974 she was found to have sitosterolemia. Representative fasting plasma lipid and lipoprotein concentrations are indicated in Table I . She has subsequently been treated with a low fat, low sterol diet and cholestyramine, 4 g, three times a day. This has nor-1. Abbreviations used in this paper: ACAT, acyl CoA:cholesterol acyltransferase; C-26 sterol, 22-trans-24-norcholesta-5,22-dien-3-jl ol; NCEH, neutral cholesteryl ester hydrolase. malized her total plasma sterol concentration, caused regression of her xanthalasma and had little change on her Achilles tendon xanthomas, which is consistent with a previous report of cholestyramine use in this disease (6) . Because neomycin also inhibits the absorption ofcholesterol (9, 10), she was given a trial of this drug. Cholestyramine was discontinued and neomycin, 1 g, orally, twice a day was given for 3 wk, at which time it was discontinued because of nausea. This drug trial was associated with a 44% increase in total plasma sterols and suggests neomycin is of little use in treating these patients. At the time of these investigations, she was 161 cm tall, weighed 66 kg, and was healthy with no symptoms of cardiovascular disease. Her physical examination was significant for xanthalasma, thickened Achilles tendons, and an abdominal bruit. She was on no medications except for cholestyramine, 12 g per day, and this was discontinued 3 wk prior to (11, 12) . The studies were performed using an approved protocol for human experimentation and informed consent was obtained from all subjects.
Sheifishfeeding study. The subject was offmedication and consuming a low fat diet (30% fat) for 3 wk prior to admission. She was admitted to the National Institutes of Health and placed on an isocaloric diet rich in shellfish for 11 d with a composition of 35% fat, 36% carbohydrate, and 29% protein with a polyunsaturated to saturated fat ratio of0.4. She was fed exactly the same diet every day, and her weight was 66±1 kg during the course of the study. In order to measure the exact intake of different sterols, a total 4-d food aliquot was obtained for sterol analysis by the methods described in the "biochemical analysis" subsection. Her oral intake per day was 42 mg of C-26 sterol, 90 mg of 22-dehydrocholesterol, 123 mg of brassicasterol, 89 mg of 24-methylene cholesterol, and 182 mg of cholesterol.
On days 0, 1, 4, 7, 9, and 11, blood was drawn after a 12-h fast into glass tubes with a final concentration of 0.1% EDTA, the plasma was separated by low-speed centrifugation in a refrigerated centrifuge, and the lipoproteins were separated by ultracentrifugation (13) .
On day 11 of the study, after a 12-h fast, a double lumen Anderson AN 20 nasogastric tube (H. W. Anderson Products, Inc., Oyster Bay, NY) was placed into the second portion ofthe duodenum and the placement was confirmed radiographically. Synthetic cholecystokinin (Kinevac, E. R. Squibb and Sons, Princeton, NJ) was injected intravenously (4.2 ug), and bile was obtained by aspiration.
All feces were collected during the course of the shellfish feeding study. The plasma, lipoprotein, bile, and fecal samples were frozen at -20°C until the sterol analyses were performed.
Measurement oftissue sterols. The patient underwent a hyserectomy in 1979 for menorrhagia while she was taking 8 g of cholestyramine per day for her elevated plasma sterol concentration. At the time of surgery samples of plasma, skin, adipose tissue, broad ligament, uterine artery, and uterine muscle were frozen in liquid nitrogen for analysis of sterols. Tissue lipids were extracted by chloroform and methanol (14) . Sterols in both plasma and tissue lipid extracts were determined by the methods described below.
Biochemical analysis. For Table I , plasma cholesterol and triglyceride levels were quantitated on a Gilford System 3500 enzymatic analyzer and high density lipoprotein (HDL) cholesterol was determined in plasma after dextran sulfate precipitation (15) . The lipoprotein cholesterol analyses were performed according to the Lipid Research Clinics methods (16) . In all other tables, the lipids were quantitated as described below.
The neutral sterol content of the diet, plasma, bile, and stool was analyzed by the methods described in detail previously (I 1, 17). Briefly, they involved saponification, extraction, digitonin precipitation, thinlayer and gas-liquid chromatography, and mass spectrometry. Authentic standards of the sterols were used for calibration. For separating the complex shellfish sterols, an additional gas-liquid chromatography column with SP-1000 packing was used, thus enabling the separation of brassicasterol from lathosterol, campesterol from 24-methylene cholesterol, and sitosterol from isofucosterol (18) . Cholestanol was separated from other sterols by argentation thin-layer chromatography and quantified by gas-liquid chromatography with a QF-l column (19) . Plasma free and esterified sterols were separated by thin-layer chromatography before quantitation (20) . For comparison, plasma and bile neutral sterols were also analyzed by a gas-liquid chromatograph equipped with glass capillary column (SE-30, 30 m) (21) . The retention times of the sterols on the different columns are given in Table II . The results of the two methods were very similar. We have utilized the capillary column data in this report.
The bile acids were analyzed by the methods previously described (22) . Samples were subjected to saponification, extraction, methylation, and thin-layer chromatography. The bile acids were converted to trifluoroacetate derivatives and determined by gas-liquid chromatography with a QF-I column.
Results
In order to determine whether the defect in sterol absorption in patients with sitosterolemia was restricted to plant sterols, we investigated the absorption of shellfish sterols in a sitosterolemia patient. The patient was fed a diet very high in shellfish, and Table III shows the changes in plasma shellfish sterols and plant sterols over time with this diet. The shellfish sterols increased 11 -fold while the plant sterols and cholesterol increased 18% and 29%, respectively. In addition, the baseline concentrations of the 5 a-saturated sterols, cholestanol, campestanol and sitostanol were increased in the plasma, as has been recently reported (6) . The baseline isofucosterol concentration was also increased while lathosterol is normally present at this concentration. The 5 a-saturated forms of the shellfish sterols were not detected. The shellfish sterols were evenly distributed in the plasma lipoprotein density subfractions (Table IV) . Plasma shellfish sterols were also esterified approximately to the same degree as the other sterols (Table IV) . Table V compares the plasma sterol levels in the subject with sitosterolemia with normal subjects previously reported by us (1 1, 12) . While on comparable diets, the sitosterolemic subject had plasma shellfish sterol levels 6 times normal, plant sterol levels 200 times normal, and cholesterol levels 1.4 times normal.
Shellfish sterol absorption. The subject was on a defined diet high in shellfish and the shellfish sterol absorption was determined by the difference between sterol intake and sterol excretion in the feces assuming that hepatic reexcretion of these sterols was negligible compared with the dietary intake. The absorption of the shellfish sterols is shown in Fig. 2 and compared with shellfish sterol absorption in normal subjects. The absorption of C-26 sterol and 22-dehydrocholesterol are -2 times normal whereas 24-methylene cholesterol is 4-5 times normal and brassicasterol is 8-10 times normal. Therefore, the subject with sitosterolemia hyperabsorbed all of the shellfish sterols quantitated.
Bile acid and neutral sterols in bile. At the completion of the shellfish sterol feeding study, bile samples were obtained from the study subject. The different acidic and neutral sterols in the bile were quantitated (Tables VI and VII) with the bile composition of normal subjects while on a comparable high shellfish sterol diet. The bile acids in the sitosterolemic subject were slightly enriched in deoxycholic acid and relatively poor in cholic acid, though these values were still within the normal range. There were minimal differences in the other bile acids (Table VI) . The fraction of total biliary sterols that was shellfish sterols was slightly higher in the study subject than in the control subjects (Table VII) , but this difference was not nearly as great as the difference between these subjects for plasma shellfish sterols (Table V) . Table VII also compares the ratio of the relative concentrations of each of the neutral shellfish sterols in bile with their relative concentration in plasma in normals and the sitosterolemic subject. The higher the ratio indicates the greater the ability of the liver to concentrate that sterol in bile in comparison with the other sterols. In normal subjects the relative concentration of biliary shellfish sterols and plant sterols were 6.3-and 25.8-fold greater than in plasma. In the sitosterolemic subject, however, the relative concentrations of biliary shellfish and plant sterols were only 2.1 and 0.7 of the relative concentration in plasma. Thus, in addition to hyperabsorption ofshellfish sterols, the sitosterolemic subject had a relative inability to concentrate these sterols in bile. Both of these abnormalities would be expected to result in an elevation of the plasma shellfish sterol concentration.
Tissue sterol content. This patient had menorrhagia and had a hysterectomy performed. The surgery was performed from an abdominal approach and samples of different tissues were obtained for identification and quantification ofsterols; the stanols were not analyzed in these samples. Table VIII shows that all tissues had substantial concentrations of plant sterols.
Discussion
Patients with sitosterolemia and xanthomatosis have an abnormality in plant sterol metabolism leading to elevated plasma plant sterol levels, tendinous xanthomas, and premature atherosclerosis (1) (2) (3) (4) (5) (6) . To gain further insights into sterol metabolism in sitosterolemic subjects, we studied the metabolism ofshellfish sterols in an individual with sitosterolemia.
Normal individuals absorb shellfish sterols and the percentage of absorption is dependent upon the structure of the particular sterol in question, e.g., the sterols that resemble cholesterol the closest (the C-26 sterol and 22-dehydrocholesterol, having 26 (12) . t Mean±SD. § These ratios were calculated by taking the ratio of a given sterol to cholesterol in bile divided by the same ratio in blood. This approach must be followed because of the invariable and inconsistent dilution of bile samples by gastric and intestinal secretions. range (data not shown). Thus, the sitosterolemic individual had an increased absorption of all the sterols evaluated. Abnormalities in the liver metabolism of sterols were also observed in the sitosterolemic patient. The level of plant sterols in plasma in normal individuals is kept low by at least two mechanisms. The first is the relatively poor absorption of dietary plant sterols (7) . The second mechanism involves the ability of the liver to excrete plant sterols preferentially in relationship to cholesterol. Salen et al. (7) found that the half-life of sitosterol was much shorter than cholesterol. In a recent study, we reported that both shellfish and plant sterols are selectively concentrated in normal bile (12) . These two pieces of evidence suggest the preferential hepatic excretion of both shellfish and plant sterols in normal subjects. In contrast, our subject with sitosterolemia had an inability to concentrate shellfish and plant sterols normally in bile. This extends the previous finding that sitosterolemia subjects do not concentrate sitosterol normally in bile (3, 5) . The present results have shown that this subject with sitosterolemia has a generalized hyperabsorption of dietary sterols, and in addition, the liver is unable to concentrate plant and shellfish sterols normally in bile, leading to elevated plasma concentrations of these sterols.
The mechanism for the development of xanthomas and premature atherosclerosis is more elusive. The composition of the sterols in the different tissues evaluated was similar to the plasma sterol composition with cholesterol being the predominant sterol (Table VII) . Therefore, the tissues did not solely accumulate abnormal sterols. This is similar to the sterol composition in xanthomas from these subjects (1, 2). It is not possible from these data to discern between the abnormal sterols directly disrupting normal intracellular sterol homeostasis leading to xanthoma formation versus all tissues having a molecular defect in the metabolism of sterols leading to a generalized accumulation of many different sterols in these tissues.
The site(s) at which the cells determine the specificity for sterol metabolism is (are) as yet unknown. Sterols are either directly synthesized from acetyl-CoA or absorbed in the gastrointestinal tract from dietary sterols. The ingested dietary sterols are solubilized by bile acids, absorbed across the intestinal mucosal cell membrane (23) , and transported in the cytoplasm by sterol carrier or binding proteins (24, 25) . Once in the cell, they either remain as free sterols or are esterified with long-chain fatty acids (26, 27) . Ifthey remain as free sterols, they are poorly absorbed into the body (28, 29) , and presumably remain within the cell which is then sloughed into the irntestinal lumen and excreted in the feces (24) . If the sterols are esterified they may be incorporated into chylomicrons and secreted into the lymphatics eventually reaching the intravascular space (26) (27) (28) (29) . The amount of intracellular free sterol and sterol ester is determined by the rate of esterification by ACAT and the rate of sterol ester hydrolysis by NCEH. Within the liver, sterols may remain as free sterols or be esterified by ACAT. If they remain as free sterols, they may be excreted into the bile either as free sterols or as bile acids after further metabolism (30, 31) . If the sterols are esterified with fatty acids, they are no longer available for secretion into bile. The fate of sterol esters in liver is not clearly known. Some may be incorporated into very low density lipoproteins (VLDL) and secreted, but most are subsequently hydrolyzed to free sterols. It is not known at the present time whether these newly hydrolyzed sterols are in free equilibrium with all free sterols in hepatocytes, or ifthey contribute to certain metabolic pools, such as the free sterols in nascent VLDL and cellular membranes, and not to other pools, such as biliary sterols and bile acids. There is evidence, though, for metabolic compartments of free sterols within hepatocytes that are not in equilibrium with other intercellular free sterol pools (31) . As in intestinal mucosal cells and hepatocytes, sterols may exist in other tissues as free sterols or sterol esters. Ifthey remain as free sterols, they may be transported to and incorporated into the cytoplasmic membrane where they are removed by HDL by reverse cholesterol transport (32) . If they are esterified, they form nonmembrane-bound lipid droplets and are stored as the ester (33) .
A unifying hypothesis for the abnormality in this subject with sitosterolemia is that the discrimination for esterification of the different sterols is lost, and that the equilibrium is shifted in the direction of more esterification of sterols. There are multiple possible sites for the recognition of structurally different sterols and control of sterol esterification including solubilization of sterols in the intestine, a sterol recognition site on plasma membranes, sterol carrier proteins, ACAT, and NCEH. ACAT is a particularly good candidate for this function with the recent observation that ACAT is able to discriminate between cholesterol and sitosterol when catalyzing the esterification of sterols in rat hepatocytes (34) and rabbit intestinal mucosal cells (35) .
The lack of specificity in intracellular esterification ofsterols leading to increased intercellular sterol esters could result in the following phenomena: First, the esterification of sterols is important for the incorporation of sterols into intestinal chylomicrons; therefore increased mucosal esterification of sterols could result in increased sterol absorption (26) (27) (28) (29) These results have important implications for the therapy of this disease. First, the metabolic abnormality in this disease involves sterols in general, not just plant sterols. Therefore, patients should be treated with a low total-sterol diet, rather than with just the avoidance of plant sterols. Secondly, it has been our experience that this patient responds to cholestyramine therapy and not to neomycin. Therefore, because of the occurrence of markedly premature cardiovascular disease in these subjects, a low fat diet with cholestyramine drug therapy would seem to be the most appropriate initial therapy at the present time.
This disease has been called by various names by different investigators. Initially it was called (l-sitosterolemia and xanthomatosis (1, 2) and subsequently phytosterolemia (3) (4) (5) , and most recently sitosterolemia and xanthomatosis (6) . We have now shown that this abnormality in sterol metabolism extends to shellfish sterols, and by inference, is probably a general abnormality in sterol recognition. We, therefore, feel that this disease should be called sitosterolemia and xanthomatosis, at least until the defect is known at a molecular level, for the following 
